Sandoz US President Peter Goldschmidt Talks Generic Policy Improvements
Executive Summary
The US is behind other markets when it comes to complex generics and biosimilars, Goldschmidt said, though he is hopeful new FDA Commissioner Gottlieb and the new administration will explore ways to make approval of hard-to-replicate drugs faster.